✨ Free AI Report
Adial Pharmaceuticals, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Adial Pharmaceuticals, Inc.
Company Research

Adial Pharmaceuticals, Inc.: Business Overview, Financials & Competitive Analysis

Adial Pharmaceuticals, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage addiction treatment company with promising precision medicine approach and recent regulatory tailwinds, but clinical and commercial execution risks remain significant given capital limitations. Recently regained Nasdaq compliance after addressing minimum bid price requirements, resolving a critical listing risk. Clinical asset in Phase 3 with regulatory clarity, but company.

What is Adial Pharmaceuticals, Inc.'s industry? Adial Pharmaceuticals, Inc. (adial.com) operates in Biopharmaceuticals - Addiction Treatment & Behavioral Health. AskCyborg classifies Adial Pharmaceuticals, Inc. under Biopharmaceuticals - Addiction Treatment & Behavioral Health in its company registry.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment and prevention of addiction and related disorders, with its lead product AD04, a serotonin-3 ant...

4/ 10Mixed

Cyborg Score thesis

Early-stage addiction treatment company with promising precision medicine approach and recent regulatory tailwinds, but clinical...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Addiction Treatment & Behavioral Health
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Adial Pharmaceuticals, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Adial Pharmaceuticals, Inc.

AskCyborg analysts argue the bull and bear cases for Adial Pharmaceuticals, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Adial Pharmaceuticals, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Adial Pharmaceuticals, Inc. Overview

Pro stress-test →

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment and prevention of addiction and related disorders, with its lead product AD04, a serotonin-3 antagonist, currently in Phase 3 clinical trials for treating alcohol use disorder. The company is pursuing a precision medicine approach with significant regulatory tailwinds and strategic partnerships in development.

Strategic Profile

Pro stress-test →

The company is advancing AD04 toward a pivotal Phase 3 program with refined clinical strategy, regulatory alignment, and manufacturing readiness. Recent federal appropriations directive on alternative clinical trial endpoints aligns with Adial's regulatory pathway for AD04, which targets Alcohol Use Disorder using a precision medicine approach.

Competitive Landscape

Pro stress-test →

Adial operates in the addiction treatment therapeutics space competing against larger pharma with alcohol use disorder programs. Primary competitors include companies developing medications for AUD such as those with naltrexone, acamprosate, and other investigational serotonin-targeted approaches. The precision medicine genotype-targeting approach of AD04 differentiates Adial's positioning within this space.

Industry Context

Adial Pharmaceuticals, Inc. operates in Biopharmaceuticals - Addiction Treatment & Behavioral Health.

Key facts

Founded: 2010 · Headquarters: Glen Allen, Virginia · Employees: 5-7 · Revenue: Unknown · Market cap: $2.8M-$8.7M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Adial Pharmaceuticals, Inc..

  • Recently regained Nasdaq compliance on Feb 23, 2026 after maintaining $1.00+ closing bid price for 10 consecutive business days
  • Lead drug AD04 targets heavy-drinking patients with specific genotypes and is in preparation for new Phase 3 adaptive program informed by FDA End of Phase 2 feedback
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Regained Nasdaq compliance with minimum bid price requirement after 10 consecutive business days at $1.00+
  • Feb 2026Congressional directive on alternative AUD trial endpoints signed, potentially reducing Phase 3 trial burden from two to one
  • +2 moreTrack every material event for Adial Pharmaceuticals, Inc. as it happens. Explore monitoring →
Get alerted when Adial Pharmaceuticals, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

NaltrexoneOpioid antagonist FDA-approved for AUD→AcamprosateFDA-approved maintenance therapy for AUD→Investigational AUD ProgramsCompeting mechanisms for addiction treatment→

Compare Adial Pharmaceuticals, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Adial Pharmaceuticals, Inc. operates in Biopharmaceuticals - Addiction Treatment & Behavioral Health. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Addiction Treatment & Behavioral Health research →
NEW · MCP server

Ask your AI assistant about Adial Pharmaceuticals, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Adial Pharmaceuticals, Inc. and its top competitor on Cyborg Score”
“What did Adial Pharmaceuticals, Inc. do this quarter?”
“Is Adial Pharmaceuticals, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Adial Pharmaceuticals, Inc. do?+
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment and prevention of addiction and related disorders, with its lead product AD04, a serotonin-3 ant...
What is Adial Pharmaceuticals, Inc.'s Cyborg Score?+
Adial Pharmaceuticals, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Adial Pharmaceuticals, Inc.'s main competitors?+
Named competitors include Naltrexone, Acamprosate, Investigational AUD Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Adial Pharmaceuticals, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Adial Pharmaceuticals, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Adial Pharmaceuticals, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.